AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

The article finds no classic warning signs of an imminent dividend cut at AbbVie, Merck, Amgen or Gilead, while emphasizing that each faces different patent and product risks. AbbVie’s Skyrizi and Rinvoq generated $5.505 billion and $2.525 billion, respectively, in Q2 as Humira sales fell 35.9% to $756 million; Amgen’s Q2 free cash flow rose 82.6% to $3.489 billion despite declines in Prolia and XGEVA. Merck’s trailing payout ratio is distorted by one-time charges, while Gilead’s HIV sales grew 12% to $5.693 billion as Veklury sales fell 81% to $23 million. The assessment is generally supportive of dividend coverage, but flags Merck’s 2028 KEYTRUDA exclusivity loss, Amgen’s $57.3 billion debt and Gilead’s reduced cash after acquisitions.

Analysis

Dividend safety is not the differentiator; replacement-asset execution is. The reassuring payout narrative is mostly backward-looking: investors should price the durability and breadth of the cash-flow bridge, not the dividend streak. ABBV has the clearest near-term replacement engine, but that makes it more exposed to execution or pricing setbacks in two products; the pending acquisition adds a competing claim on cash and deleveraging capacity. MRK’s key risk is a two-stage squeeze: growth can slow before exclusivity ends, leaving less time to establish replacement revenue. The new formulation may soften the transition, but its ability to preserve economics remains unverified. AMGN’s biosimilar business is a partial natural hedge to biosimilar erosion elsewhere in the portfolio, though it does not remove the balance-sheet constraint. GILD’s HIV franchise supports the current payout, but reduced cash after acquisitions raises the cost of a disappointing launch or regulatory outcome.

Positioning: Relative execution favors ABBV over MRK, but this is a bridge-quality trade, not a claim that ABBV is low-risk. A broad pharma or dividend-yield trade is less compelling: a payout can remain covered while the market marks down the durability of the earnings base. Near term, dividend reassurance may have limited incremental power. Over 1–3 months, watch product trends and guidance for evidence of replacement growth; over 6–18 months, MRK’s pre-2028 pipeline conversion and GILD’s launch uptake matter more. The contrarian risk is that investors treat all four payouts as equally secure and underprice concentration and reinvestment risk. No dividend-cut thesis is established by these facts.

Key Decisions for Investors

• Consider a modest, dollar-neutral long ABBV / short MRK pair as a relative replacement-growth expression, not a dividend-cut trade. Reassess if ABBV’s Skyrizi/Rinvoq growth materially decelerates, leverage fails to track toward management’s stated target, or MRK demonstrates sustained growth beyond KEYTRUDA. Do not infer valuation cheapness from the supplied forward P/Es alone.
• Keep AMGN on a watchlist rather than adding solely for dividend safety. Track free cash flow after debt service, net-debt progress, and whether growth products offset Prolia/XGEVA and Enbrel erosion; MariTide remains a development-stage option, not current coverage.
• For GILD, avoid pre-committing to a binary regulatory trade. Track Yeztugo uptake, HIV portfolio growth, cash rebuilding, and the stated FDA decisions; weaker launch traction or a further liquidity decline would undermine the payout cushion.
• Falsifiers across the group: a material reduction in adjusted earnings or free-cash-flow guidance, dividend growth paused alongside deteriorating coverage, or replacement-product growth failing to offset legacy-product erosion. Confirm these measures in filings and subsequent earnings before sizing positions.